MSB

10.4%

$1.49 mesoblast limited

Mr Lassman— disgruntled Hot copper poster ? Two spring to mind...

First 1008 Last

Share
Profile

Follow
Kerebrad

2,439 Posts.

476

13/07/23

07:30

Post #: 68759566
Share

Originally posted by dachopper: ↑

Now here's where you really go off the rails with "full of confounded questions that make no sense" and "baseles accusations". You don't really want to leave it up the the FDA, just to make sure you take the shot gun out and trigger both barrels. You actually want to offer a completely negative and extreme opinion about the content of the petition...

Not quite - I'm being factual, but yes the lassman law petition looks like it was written by a pre-schooler. Best you have a look at my post on the countdown thread.... the first confounded questions are Lassman comparing a disease severity grade Control response, to a non disease severity grade control response - as if the outcome has any significance whatsoever to Mesoblasts control arm rate. Which it doesn't. So yes.... the number of counfounding statements is vast, and false claims there are plenty of such as Mesoblast providing no new data. ( that made me laugh ), and Mesoblast submitting the BLA in October - ( another lie )
Plenty of them in there, it's a good fiction read that can easily trick the gullible into thinkng they were real problems.

An entirely reasonable post. Not sure of the relevance of the other letter to Mr Lassman.No obvious relationship to the Remestemcel BLA? Although in broad terms it does refer to the reasons for denying approval of a new drug according to the FDA's protocols regarding assesment of safety and efficacy.

Hahahahaha

Kind of like in the Lassman letter... I'm not sure of the relevance of comparing the control arm response rates, where 20% are Grade 3/4 with Macmillan trial, and 88% are grade 3/4 with Mesoblast trial. Talk about post hoc cherrypicking. Lassman must own a cherry farm, and a cherry picker with those sweeping broad categorical assumptions.

Expand

Mr Lassman— disgruntled Hot copper poster ? Two spring to mind !!

MSB Price at posting: $1.25 Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BUX

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

First 1008 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.49		Change 0.140(10.4%)		Mkt cap ! $1.701B

Open	High	Low	Value	Volume
$1.37	$1.54	$1.37	$23.10M	15.82M

Buyers (Bids)

No.	Vol.	Price($)
3	24758	$1.49

Sellers (Offers)

Price($)	Vol.	No.
$1.49	73626	3

View Market Depth

No.	Vol.	Price($)
1	10033	1.485
4	53700	1.480
1	770	1.475
3	62048	1.460
1	50000	1.455

Price($)	Vol.	No.
1.490	21995	1
1.505	24000	1
1.510	13666	2
1.515	99798	1
1.520	27250	3

Last trade - 16.10pm 04/10/2024 (20 minute delay)

MSB (ASX) Chart

Mr Lassman— disgruntled Hot copper poster ? Two spring to mind...

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Mr Lassman— disgruntled Hot copper poster ? Two spring to mind...

Top Stories

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Buxton projects new graphite province discovery at WA Narryer play

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News